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Abstract  
Inherited thrombocytopenias are a rare heterogeneous group of disorders 
characterised by a low platelet count and sometimes associated with excessive 
bleeding, ranging from mild to severe.  A cohort of 36 patients and 17 family 
members all displaying a reduced platelet count were recruited to the UK-GAPP 
(Genotyping and Phenotyping of Platelets) study.  All patients had a history of 
excessive bleeding.  Critically, all major known causes of inherited thrombocytopenia 
(e.g. MYH9-related disorder, Bernard Soulier syndrome and Wiskott-Aldrich 
syndrome), had been ruled out prior to enrolment.  Platelet phenotyping and whole 
exome sequencing was performed on all patients, resulting in identification of 
mutations in the novel gene SLFN14 in 12 patients from three unrelated families. All 
patients displayed an analogous phenotype of moderate thrombocytopenia, enlarged 
platelets, decreased ATP secretion upon stimulation with platelet agonistsmeasured 
by lumiaggregometry and a dominant inheritance pattern. SLFN14 codes for a 
protein of unknown function, Schlafen family member 14 (SLFN14). Three 
heterozygous missense mutations predicting p.K218E, p.K219N, p.V220D 
substitutions within an ATPase-AAA-4, GTP/ATP binding region were identified in 
affected but not unaffected family members. Platelets from all three families had a 
marked reduction in expression of endogenous SLFN14.  This corresponded with 
expression studies in HEK293T cells which demonstrated a significant reduction in 
all three mutants relative to the wild type protein, suggesting instability.  Electron 
microscopy studies demonstrated a significant reduction in the number of dense -
granules in  patient platelets from affected patients relative to those from healthy 
volunteers healthy control platelets, correlating with a decrease in measuredd ATP 
secretion using lumiaggregometryphenotype. Together these results identify 
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mutations in SLFN14 as causeative for an inherited thrombocytopenia and significant 
bleeding, outlining a fundamental role for SLFN14 in platelet formation and 
megakaryopoiesis.  
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Introduction  
Inherited thrombocytopenias are a group of heterogeneous disorders associated with 
bleeding of varying severity depending both on the reduction in platelet count and 
whether there is associated altered qualitative platelet function (1). The normal range 
of platelet count in humans is wide (150-400x109/L), but platelet count is normally 
maintained within a narrow range for each individual. This homeostasis requires a 
constant balance between thrombopoiesis, which is primarily controlled by the 
cytokine thrombopoietin (TPO), and platelet senescence and consumption. Heritable 
forms of thrombocytopenia are usually caused by mutations in genes involved in 
platelet production and megakaryocytic differentiation. Just over 20 forms of 
inherited thrombocytopenia have been described to date in OMIM 
(http://www.ncbi.nlm.nih.gov/omim), however in approximately 50% of patients with 
an inherited thrombocytopenia a causative gene remains to be identified (2, 3).  
Identification of such genes is fundamental to providing information on proteins 
involved in normal platelet physiology and is critical for developing our understanding 
of disease pathogenesis.   
To date the UK-GAPP Study (4) has investigated over 500+ patients 
displaying platelet dysfunction associated with excessive bleeding of unknown 
aetiology, and has identified a platelet defect in approximately 60% of participants.  A 
key criterion for recruitment is that known genetic causes of platelet dysfunction have 
been ruled out on the basis of functional studies and targeted gene sequencing. 
Platelets from patients recruited to this study undergo extensive phenotypic analysis, 
including lumiaggregometry ation to a variety of platelet agonists and detailed 
analysis of platelet number and morphology. This phenotypic analysis is then 
followed by Whole Exome Sequencing (WES) which has greatly enhanced the 
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probability and speed of identifying novel causative gene mutations in such 
conditions (5-7). In this study, we demonstrate how combined phenotyping and 
genotyping has enabled us to identify three single nucleotide variations in a novel 
gene SLFN14,  predicting substitutions of three consecutive amino acids in SLFN14, 
in three unrelated families displaying a moderate form of congenital 
thrombocytopenia and a strong bleeding history.  In all individuals in which these 
mutations were found the bleeding history was more severe than would have been 
predicted on platelet count alone and was associated with a similar reduction in 
platelet count, reduced aggregation and ATP secretion to several platelet agonists 
including ADP, collagen and a PAR-1-activating peptide. This phenotyping and 
genotyping approach has identified SLFN14 as causative gene for a new form of 
platelet thrombocytopenia. 
 
Results and Discussion  
There are approximately 3,000 patients with platelet function disorders associated 
with excessive bleeding within the UK Comprehensive Care Haemophilia Centres, of 
which approximately 10% have a reduced platelet count. A candidate gene mutation 
has not been identified in approximately 50% of these patients.  Over the course of 
the last 6 years, we have recruited over 500+ patients from 25 (~2/3rds) UK 
Haemophilia Care Centres with excessive bleeding and suspected platelet function 
disorders to the UK-GAPP Study. 60 (13%) of these patients have been classified as 
having a low platelet count of unknown cause. The combination of a strong family 
history of low platelet count and significant bleeding platelet function defect allowed 
us to prioritise these for gene identification studies. WES was performed and 
analysis was undertaken in 53 patients (36 index cases) who had reduced platelet 
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counts ranging from 15-140 x 109/l. Family A had 9 affected  members over three 
generations with a strong history of bleeding and moderate thrombocytopenia with 
platelet counts ranging from 74-140 x 109/l (Figure 1A and Table 1). The proband, 
IV:4, was aged 31 years and had a platelet count of 100x109/l when entered into the 
study.  She had a history of frequent and severe cutaneous bruising, prolonged 
bleeding from minor wounds, menorrhagia, postpartum haemorrhage and 
spontaneous muscle haematoma. Several other members of family A also had 
significant bleeding histories and moderate thrombocytopenia (Table 1). 
The gold-standard test for platelet function testing is Born aggregometry, but 
increased information can be obtained by real-time measurement of secretion of 
ATP (lumiaggregometry) (8). We tested affected members of family A (III:2, III:3, 
IV:2, IV:4 and IV:5) and observed reduced aggregation to ADP (10 and 30µM), 
collagen (3µg/ml and 10µg/ml) and PAR-1 activating peptide (100 µM) with reduced 
ATP secretion (Figure 2, A-B). The similar platelet phenotype in the affected 
individuals of family A was consistent with a dominant mode of inheritance. 
Sequencing of the exomes of DNA from IV:2, IV:4 and III:3 in family A 
revealed 22867, 23334 and 23153 sequence variations, respectively. Comparisons 
with dbSNP build 135, the 1000 Genomes project database and our in-house 
database (composed of >600 exomes) identified 124, 137 and 128 heterozygous 
novel variants, respectively. Of these only 8 variants were shared by the 3 affected 
patients of which 4 were significant including 3 non-synonymous variants and 1 
frameshift deletion. Sanger sequencing of these remaining 4 variants in all 
individuals in family A left two remaining candidate variants in NEMF (p.H962Y) and 
SLFN14 (p.V220D) that segregated with disease (Supplementary Table 1). The 
exomes of the further 35 index patients with thrombocytopenia and/or secretion 
7 
 
defects who had been recruited to the UK-GAPP study were scrutinised for novel 
variants in either the NEMF or SLFN14 genes. Two further heterozygous missense 
variants were identified in SLFN14 in affected members of family B (p.K219N) and 
family C (p.K218E) (Table 1 and Figure 1, A-B). Strikingly, all three missense 
mutations were predicted to result in substitutions in a three amino acid stretch of the 
ATPase-AAA-4 domain of the protein encoded by SLFN14, schlafen family member 
14 (Figure 1B).  Furthermore the three SLFN14 variants are not present in 
the Exome Aggregation Consortium dataset of 61,486 unrelated individuals 
sequenced as part of various disease-specific and population genetic studies 
(http://exac.broadinstitute.org/gene/ENSG00000236320) and the latest version of 
dbSNP138.  
Affected members of families B and C had remarkably similar platelet counts 
and platelet function defects. Family B included three patients, two of whom were 
recruited to the study (I:2, II:3). The proband in family B (II:3) was 35 years old when 
recruited to the study and had a platelet count of  68x109/l with  a history of 
spontaneous epistaxis starting in childhood.  Her mother (I:2) had a platelet count in 
whole blood of 83x109/L with a less severe bleeding history. The platelet count in II:3 
was too low for lumiaggregometry (8) and so platelet function was analysed by flow 
cytometry for P-selectin expression, revealing reduced responses to CRP and PAR-
1 peptide (Table 1). In line with this, lumiaggregometry on I:2 revealed 
deaggregation to ADP, collagen and PAR-1 and reduced ATP secretion (Table 1). 
These results are similar to those seen in affected members of family A (Figure 2A-
B).  
The index case in family C, II:2 was aged 3 years at the time of enrolment. His 
platelet count in whole blood was 89x109/l and he was noted to bruise easily from a 
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young age. The lumiaggregometry findings in this patient are similar to those of other 
study participants from families A and B with a selective loss of response to ADP, 
collagen and PAR-1 and normal responses to arachidonic acid (Table 1, Figure 2, 
Supplementary figure 1).   
 In humans and mice SLFN14 is located in a SLFN cluster with other schlafen 
paralogues (9). Members of the SLFN gene family are highly conserved amongst 
mammalian species and lower vertebrates, and even in viruses. SLFN family 
proteins contain a unique motif of unknown function, the ³6/)1 ER[´DQGan AAA 
domain. The AAA+ domain consists of a P-loop NTPase which is implicated in 
ATP/GTP binding and hydrolysis (10). The SLFN family membersy are divided into 
three groups.  SLFN 5, 8, 9, 10 and 14 all belong to group 3, although SLFN14 is 
unique in containing a putative nuclear localisation RKRRR motif in its C-terminus 
extension (10). The SLFN family of proteins have been suggested to be critical for a 
variety of processes including cell-cycle regulation, proliferation and differentiation 
(10-14), however there is no published data about the function of SLFN14.  
Rowley et al., 2011 (15) previously described SLFN14 mRNA expression in 
human and murine platelets. We also identified expression of SLFN14 mRNA and 
protein in immature and mature megakaryocytes derived from CD34+ hematopoietic 
progenitor cells isolated from cord blood (Supplementary Figure 2). Expression of 
SLFN14 protein was confirmed by Western blotting of platelets from 11 healthy 
individuals, normalized for GAPDH loading control (Supplementary Figure 3). Levels 
of SLFN14 in healthy volunteers ranged from 1.0 to 2.3 arbitrary units (mean 1.5, 
95% CI 1.2 to 1.8).                   
The effect of the SLFN14 variants on protein expression in platelets from 
affected family members was investigated by Western blotting (Figure 3A).  Platelet 
Field Code Changed
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lysates from carriers of the three SLFN14 variants showed a 65-80% reduction in 
SLFN14 protein expression when compared to control platelets (Figure 3 A-B).  
Patient III:2 from family A expressing the p.V220D mutation demonstrated a 
reduction in SLFN14 expression to ~24% of control (Pӊ0.001), both patients I:2 and 
II:3 from family B expressing the K219N mutation showed a reduction to 33% (Pӊ
0.005) and 34% (Pӊ0.001) respectively, and patient II:2 from family C expressing the 
K218E mutation showed a decrease to 19% (Pӊ0.001). This reduction in SLFN14 
levels in all three patients is over 50% despite the heterozygosity suggesting that the 
mutant gene/protein influences the translation of mRNA or stability of the wild type 
protein (e.g. due to protein dimerization).  Significantly, the reduction in SLFN14 
levels in platelets from carriers of the SLFN14 variants was confirmed in 
overexpression studies, where despite there being no significant difference in 
transfection efficiency, average field of view intensity measurements and western 
blot analysis demonstrated a significant reduction in expression of all SLFN14 
variant constructs compared to the wild type construct i.e. SLFN14(K218E)-myc, 
SLFN14(K219N)-myc and SLFN14(V220D)-myc expression was reduced to 5%, 8% 
and 52% of SLFN14(WT)-myc expression respectively (Supplementary Figure 4).  
The much larger reduction in both SLFN14(K218E)-myc and SLFN14(K219N)-myc 
expression may be a result of increased instability in these mutations in comparison 
to the SLFN14(V220D)-myc. 
Expression of SLFN14(WT)-myc in HEK293T cells revealed a punctate 
structure localized throughout the cytoplasm, with low level nuclear punctate staining 
also observed.  No significant difference in protein localization was observed 
between overexpression of all SLFN14 mutants and the wild type construct 
(Supplementary figure 5).      
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 The morphology of platelets derived from patients carrying heterozygous 
SLFN14 mutations was examined by transmission electron microscopy (TEM). 
Compared with healthy control platelets from healthy volunteers the number of 
alpha-granules and other organelles present per platelet section showed a small 
increase but this was not statistically significant (Supplementary Figure 6).  A small 
increase in platelet area was also observed corresponding with data shown in Table 
1, however a statistically significant increase was only observed in patient I:2 of 
Family B (Pӊ0.005).  When alpha granule number was normalized to account for 
surface area, no significant difference was observed (Figure 3C and D).  
Whole mount electron microscopy was utilized in order to quantify electron 
dense granules (dense granules) within platelets of both affected patients and 
healthy control plateletsvolunteers.  A significant reduction in the number of dense-
granules was observed in patient platelets from families A and B, patients IV;4 and 
II:3 respectively (Figure 3E and F).  Decreased platelet dense granule contentThis 
observation correlates with boththe reduced ATP secretion measured by 
lumiaggregometry (Figure 2). Spreading of platelets on fibrinogen was not 
significantly different in platelets between affected individuals and healthy controls 
(Supplementary figure 7).  
Finally, we examined megakaryocytes derived from CD34+ cells isolated from 
the peripheral blood of patients or healthy donors.  We saw no significant difference 
in the level of ploidy between megakaryocytes derived from healthy donors or 
patients from Family A (patient IV;4) or Family B (patient II:3) (Supplementary figure 
8).  Proplatelet formation was also examined and a small but significant decrease in 
the number of megakaryocytes bearing tubulin positive proplatelet-like extensions 
was reduced from ~20% in control megakaryocytes to ~11% in patient A IV;4, a non-
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significant reduction to ~16% was observed in megakaryocytes derived from patient 
II:3 from family B.  This data may be indicative of decreased proplatelet formation in 
patients carrying heterozygous SLFN14 mutations. 
 To further investigate the effect of SLFN14 on ploidy levels, DAMI cells were 
treated with siRNAs against SLFN14 (SLFN14-s50927 and SLFN14- s50928) or with 
a non-silencing control (control-siRNA). SLFN14 mRNA levels were reduced by 50% 
in DAMI cells  for both siRNAs (Supplementary figure 9). However knockdown of 
siRNA by SLFN14 did not effect ploidy levels after 72 hours when compared with 
control cells (control-siRNA transfection), corresponding with findings in patient 
derived megakaryocytes. 
In summary we report 3 unrelated families with a dominantly inherited 
moderate thrombocytopenia with more severe bleeding than would have been 
predicted from their platelet count alone. We have used a combination of extensive 
platelet phenotyping and WES to identify three mutations in a novel gene, SLFN14 
that underlies a moderate thrombocytopenia and platelet secretion defects. The 
patients have a distinct platelet phenotype with loss of responses to ADP, collagen 
and PAR1. Together the reduced aggregation to ADP, collagen and PAR-1 may 
points towards a defect in the Gi signalling pathway. A reduction in  dense granule 
secretion may also result in a loss of positive feedback during platelet activation. 
Patient platelets from affected patients display a relatively normal ultra-structure 
howeverbut show a significant reduction in dense granule number, correlating with 
secretorylumiaggregometry data showing decreased ATP secretion and storage.  
Finally analysis of megakaryocytes isolated from patient peripheral blood show 
decreased proplatelet formation in comparison to control megakaryocytes.  This 
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study is the first description of a major role for SLFN14, in human disease and 
suggests that it has a critical function in platelet formation and megakaryopoiesis.    
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Methods 
Extensive methods are detailed in supplementary methods.  
 
Study approval 
The GAPP study was approved by the National Research Ethics Service Committee 
West Midlands ± Edgbaston (REC reference: 06/MRE07/36) and participants gave 
written informed consent in accordance with the Declaration of Helsinki. This study 
was registered at www.isrctn.org as #ISRCTN 77951167. The GAPP study is 
included in the National Institute of Health Research Non-Malignant Haematology 
study portfolio, ref 9858. 
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Table 1 
Family 
/Patient 
ID 
SLFN14 
nucleotide 
alteration 
¥ 
Effect on 
SLFN14 
Protein 
Platel
et 
count 
(x109/
L)^ 
Mean 
Platel
et 
Volum
e (fL) 
(7.83-
10.5)^ 
ISTH 
BAT 
scor
e ȥ 
Lumiaggregometry/ 
Flow cytometry 
defects 
ATP 
Secreti
on  
nmol/1
x108 
platele
ts* 
Family 
A; II:1 
c.659 T>A p.Val220Asp NA NA NA NA 
 
NA 
Family 
A; III:2 
c.659 T>A p.Val220Asp 140 9.1  5 ADP (10, 30, 100 ȝ0)  
collagen (1, 3 µg/ml) 
PAR-1 (100 ȝ0) 
0.81  
Family 
A; III:3 
c.659 T>A p.Val220Asp 74 10.4 10 ADP (10 ȝ0 
collagen (3 µg/ml) 
PAR-ȝ0 
0.42 
Family 
A; IV:2 
c.659 T>A  p.Val220Asp 110 9.3 13 ADP (10, 30 ȝ0) 
collagen (1, 3 µg/ml) 
PAR-1 (100 ȝ0) 
ND 
Family 
A; IV:4 
c.659 T>A p.Val220Asp 100 11.1 22 ADP (30 ȝ0),  
collagen (3 µg/ml)  
PAR-1 (100 ȝ0)  
0.28  
Family 
A; IV:5 
c.659 T>A p.Val220Asp 116 11.2 
 
21 ADP (10 ȝ0) 
collagen (3 µg/ml) 
PAR-1 (30 ȝ0) 
0.48  
Family 
B; II:3 
c.657 A>T p.Lys219Asn 68 11.9 20 Flow cytometry 
reduced responses to 
high conc. CRP and 
PAR-1 
NA 
Family 
B; I:2 
c.657 A>T p.Lys219Asn 83 11.9 13 ADP (10, 30 ȝ0),  
collagen (3, 10 µg/ml) 
PAR-1 (ȝ0) 
0.63  
Family 
C; II:2 
c.652 A>G p.Lys218Glu 89 13.0 NA ADP (10, 100 ȝ0) 
collagen (1, 3 µg/ml)  
PAR-1 100 ȝ0 
0.12 
 
Heterozygous nucleotide changes present in SLFN14 and their predicted effects on the resulting 
protein are shown. Index cases are indicated in bold font; ¥ Alterations are numbered according to 
positions in the NM_001129820; ^Mean platelet counts are shown, normal reference range is 150-400 
x 109 platelets/L, thrombocytopenia is defined as platelet count <150 x 109 platelets/L; ȥ ,67+
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bleeding assessment tool score, 95th percentile (score of 4) calculated from healthy volunteers (16); 
*ATP secreted in response to 100 PM PAR-1 receptor specific peptide SFLLRN, 5th centile in healthy 
volunteers is 0.82 nmol / 1x108 platelets. ND= not detectable. NA= not available 
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Figures and legends 
Figure 1 
 
 
Figure 1. Identification of SLFN14 mutations in 3 unrelated families with a 
dominant form of thrombocytopenia.  (A) Pedigrees from 3 families with moderate 
thrombocytopenia. Affected individuals are shaded, in some individuals the platelet 
count is not known (?). Asterisks indicate those patients whose exomes were 
sequenced. Representative Sanger sequencing electropherograms confirming the 
presence of the SLFN14 mutations in patients are shown below the relevant families. 
Black arrows indicate the nucleotide change. SLFN14 mutation status is shown for 
individuals that were genotyped as +/- for heterozygous state or -/- for wild type state 
(B) Linear domain organisation of SLFN14 protein showing the amino acid position 
of each of the 3 different missense SLFN14 mutations (K218E, K219N, V220D) 
located in the ATPase-AAA-4 domain and conservation of the protein in higher order 
species.  
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Figure  2  
 
  
Figure 2. Platelet phenotyping of patients from the 3 families with SLFN14 
mutations (A) Impaired aggregation in PRP from patients represented from of each 
of the 3 families (Family A; IV:4, Family B; III:3, Family C; II:2 and representative 
control) following lumiaggregometry performed on native undiluted PRP to assess 
percentage aggregation after stimulation with ADP (10PM), collagen (3Pg/ml) and 
PAR1-peptide (100PM). (B) Reduced ATP secretion from dense granules in 
representative patients from each of the 3 families using Chronolume® after 
stimulation with PAR1-peptide (100PM). (C) Flow cytometric assessment of platelet 
function in PRP from patient III.2 from family A. Responses to different agonists are 
determined using anti-CD62P. Data for healthy volunteers shown as mean + SD 
(n=9). Isotype control = IgGk1.  Data for healthy volunteers 1 in 3 dilution (with PBS) 
shown to demonstrate expected effect of moderate thrombocytopenia alone on this 
assay.  
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Figure 3 
Figure 3. Functional characterisation of SLFN14 in patient platelets. (A) 
Western blot analysis of both healthy control and patient platelet lysates, 
demonstrating significantly decreased SLFN14 protein levels in platelets from 
carriers of the SLFN14 variants when compared with platelets from healthy 
individuals.  (B) Quantification of 4 repeats of the experiments shown in A, **Pӊ0.005 
and ***Pӊ0.001 when compared to control. (C) Transmission electron micrographs of 
patient platelets showing normal morphology in comparison to healthy control 
platelets.  (D) Quantification of (C) demonstrating no significant difference in alpha 
granule number per µm2 between patient and heathy control platelets.  (E) 
Quantification of whole mount EM images of patient/health donor platelets (F) 
showing a reduction in the number of dense granules in patient platelets from 
affected patients in comparison to those from healthy volunteerscontrols, *Pӊ0.05 
and ***Pӊ0.001 when compared to control. At least 40 platelets analysed per patient/ 
healthy volunteercontrol. All values are mean ± SD.   
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